Скачать или смотреть Breakthrough Drug Combo Cuts Death Risk in Aggressive Prostate Cancer | EMBARK Trial Explained

Discover how a groundbreaking combination therapy of leuprolide and enzalutamide is revolutionizing the treatment of high-risk, recurring prostate cancer. Learn about the EMBARK trial results, which show a 40% reduction in death risk for patients with locally advanced prostate cancer. This video explains how the dual approach works, targeting testosterone to starve cancer cells, and highlights the importance of early screening. Hear from leading oncologists and understand why this readily available treatment is a game-changer for men's health.
Key topics covered:
How leuprolide and enzalutamide work together to combat prostate cancer
Real-life patient success story: Suresh Patil’s journey with aggressive prostate cancer
Insights from the Phase III EMBARK trial published in the New England Journal of Medicine
The importance of PSA screening and early detection for better survival outcomes
Who should get screened and at what age, according to the American Cancer Society
Don’t miss this essential information for anyone affected by prostate cancer or interested in men’s health advancements. Subscribe for more updates on cancer research and treatment breakthroughs!